Overall verdict
Neutral
4.6/10
1-year performance
+2.02%
Score breakdown
Up 2.0% over 1 year, 95% of the 52-week range.
Strongest: Financial strength 9.5/10. Weakest: Shareholder return 1.9/10.
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts ; AlloMap, for heart transplant follow up ; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies ;
TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus ; EBX molecular biology ranges in the field of infectious diseases ; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris.
It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Sector
Health Care
Industry
Biotechnology
Primary listing
Euronext
France
CEO
Denis Fortier
Founded
1997
Employees
343
Revenue / employee
505 497 EUR
Next earnings
April 14, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
25.50 EUR
52-week low
19.20 EUR
1-year performance
2.02%
Rising
Year-to-date performance
2.02%
Rising
Drawdown
-1.18%
Near its high
Position in the 52-week range
95% of range
Against the world ETF
Over 21 years, from November 2005 to September 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 4.1 times harder.
10 000 € placed at the end of November 2005 are worth today
| Eurobio Scientific | 3 586 € |
| World ETF | 59 929 € |
| CAC 40 | 33 291 € |
| Risk-free placement | 12 912 € |
The risk
- Shaking:the share moves 4.1 times as much as the world ETF.
- Worst fall:-99 % between March 2006 and December 2018. 10 000 € placed at the top fell to 111 €. The world ETF, at worst: -49 %. The share has not returned to its high yet.
Eurobio Scientific earned less than the world ETF since 2005
Value of 10 000 € placed at the end of November 2005, dividends reinvested, in euros
- Eurobio Scientific: 3 586 €
- World ETF: 59 929 €
- CAC 40: 33 291 €
- Risk-free placement: 12 912 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 30.00 EUR - 30.00 EUR (2 methods agree)
The price implies growth of 16.76% per year; the company grows at -10.00%.
Gross margin 43.7%, net margin 4.2%, ROIC 3.7%, ROE 3.9%.
Net margin
4.18%
Low
Sector -224.99%|S&P 13.15%
Gross margin
43.70%
High
Return on equity (ROE)
3.90%
Low
Sector -58.98%|S&P 16.61%
Return on invested capital (ROIC)
3.68%
Low
Free cash flow margin (FCF)
2.93%
Low
Profit-to-cash conversion (FCF conversion)
0.70x
High
Margin stability
20.1 pts
Very uneven
Revenue to net income
Growth
4.6/10Revenue up 4.5% over 1 year, -2.2% a year over 5, EPS -40.6% a year over 5.
Revenue (trailing 12 months)
172M EUR
Revenue growth (1y)
4.50%
Hyper-growth
Revenue growth (3y)
10.48%
Moderate
EPS growth (1y)
21.29%
Solid
EPS CAGR (5y)
-40.59%
Declining
EPS revisions (3 months)
0.00%
Revised down
Valuation
5.8/10P/E 35.3x, forward P/E 22.3x, EV/EBITDA 6.7x, PEG 0.17. The multiple sits in the 74th percentile of its own 5-year history.
P/E (TTM)
35.3x
Very expensive
Sector 11.3x|S&P 24.1x
Forward P/E
22.3x
Expensive
EV / EBITDA
6.7x
Cheap
Sector 15.2x|S&P 15.2x
PEG
0.17
Growth unpriced
Sector 1.61|S&P 0.90
Fair value (reverse DCF)
30.00 EUR
Undervalued
P/E vs its own 5-year history
among the 26% highest valuations
Pricier than usual
Market cap
248M EUR
Financial strength
9.5/10Cash covers 178.7% of the debt, net debt/EBITDA -0.1x.
Net debt / EBITDA
-0.1x
Very solid
Gearing (net debt / equity)
-6.17%
Net cash
Cash
25.6M EUR
Cash / market cap
10.34%
Solid
Cash / total debt
178.68%
Net cash
Interest coverage
10.1x
Very solid
Net debt
-11.3M EUR
Equity
183M EUR
Closed daily candles, 2 years
Last close on October 21, 2026: 25.20 EUR
- MM2025.17
- MM5022.64
- MM20022.55
- RSI 1471.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.42%
200-day average slope, 3 months
-2.84%
50-day average slope, 1 month
+8.28%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
0.25 % per day
Volatility change
-89.68%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.13 (1) | 1.13 (1) | 176 (1) | 32 (1) | 12 (1) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | ALERS | 4.6 | 4.8 | 278M USD | 35.3x | 4.2 % | 4.5 % | 3.7 % | -0.1x | 2.0 % | 2.0 % | ||
| 6 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 7 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 8 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 9 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % |
